← Back to Discover
Vestal Point Capital, LP
Period ended Jun 30, 2026 · Latest filing Aug 14, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $4,279,457,817
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- BioMarin Pharmaceutical Inc · COM · 09061G101 · shares: $344,750,500
- Neurocrine Biosciences Inc · COM · 64125C109 · shares: $316,845,800
- Abivax SA · SPONSORED ADS · 00370M103 · shares: $313,086,774
- United Therapeutics Corp · COM · 91307C102 · shares: $235,696,050
- Enliven Therapeutics Inc · COM · 29337E102 · shares: $203,000,000
- Nurix Therapeutics Inc · COM · 67080M103 · shares: $195,293,000
- Bicara Therapeutics Inc · COM · 055477103 · shares: $155,872,500
- Taysha Gene Therapies Inc · COM SHS · 877619106 · shares: $132,216,150
- Arrowhead Pharmaceuticals Inc · COM · 04280A100 · shares: $128,378,250
- Abbott Laboratories · COM · 002824100 · shares: $127,036,000
Reported holdings
68 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc | COM | 09061G101 | — | 6,025,000 shares | $344,750,500 |
| Neurocrine Biosciences Inc | COM | 64125C109 | — | 1,880,000 shares | $316,845,800 |
| Abivax SA | SPONSORED ADS | 00370M103 | — | 2,349,443 shares | $313,086,774 |
| United Therapeutics Corp | COM | 91307C102 | — | 435,000 shares | $235,696,050 |
| Enliven Therapeutics Inc | COM | 29337E102 | — | 4,000,000 shares | $203,000,000 |
| Nurix Therapeutics Inc | COM | 67080M103 | — | 8,050,000 shares | $195,293,000 |
| Bicara Therapeutics Inc | COM | 055477103 | — | 5,250,000 shares | $155,872,500 |
| Taysha Gene Therapies Inc | COM SHS | 877619106 | — | 19,415,000 shares | $132,216,150 |
| Arrowhead Pharmaceuticals Inc | COM | 04280A100 | — | 1,575,000 shares | $128,378,250 |
| Abbott Laboratories | COM | 002824100 | — | 1,400,000 shares | $127,036,000 |
| Zimmer Biomet Holdings Inc | COM | 98956P102 | — | 1,400,000 shares | $120,526,000 |
| Disc Medicine Inc | COM | 254604101 | — | 1,550,000 shares | $113,367,000 |
| Monte Rosa Therapeutics Inc | COM | 61225M102 | — | 4,600,000 shares | $111,320,000 |
| Insulet Corp | COM | 45784P101 | — | 670,000 shares | $102,007,500 |
| Ascendis Pharma A/S | ORD SHS | K08588103 | — | 375,000 shares | $100,020,000 |
| AstraZeneca PLC | ORD | G0593M107 | — | 450,000 shares | $85,329,000 |
| Sanofi SA | SPONSORED ADR | 80105N105 | — | 2,000,000 shares | $85,320,000 |
| Revolution Medicines Inc | COM | 76155X100 | — | 450,000 shares | $84,276,000 |
| BioCryst Pharmaceuticals Inc | COM | 09058V103 | — | 8,300,000 shares | $83,000,000 |
| Dyne Therapeutics Inc | COM | 26818M108 | — | 3,375,000 shares | $74,958,750 |
| Nektar Therapeutics | COM NEW | 640268306 | — | 1,000,000 shares | $69,810,000 |
| Globus Medical Inc | CL A | 379577208 | — | 850,000 shares | $67,158,500 |
| Tarsus Pharmaceuticals Inc | COM | 87650L103 | — | 1,050,000 shares | $66,087,000 |
| Immatics NV | SHS | N44445109 | — | 6,175,000 shares | $62,552,750 |
| Trevi Therapeutics Inc | COM | 89532M101 | — | 3,100,000 shares | $57,815,000 |
| Immunocore Holdings PLC | ADS | 45258D105 | — | 1,800,000 shares | $57,150,000 |
| Repligen Corp | COM | 759916109 | — | 400,000 shares | $54,576,000 |
| Bristol-Myers Squibb Co | COM | 110122108 | — | 800,000 shares | $46,096,000 |
| uniQure NV | SHS | N90064101 | — | 935,000 shares | $43,066,100 |
| Xenon Pharmaceuticals Inc | COM | 98420N105 | — | 700,000 shares | $42,252,000 |
| Bright Minds Biosciences Inc | COM NEW | 10919W405 | — | 545,000 shares | $38,259,000 |
| Madrigal Pharmaceuticals Inc | COM | 558868105 | — | 65,000 shares | $34,901,750 |
| Alcon AG | ORD SHS | H01301128 | — | 500,000 shares | $33,550,000 |
| Myriad Genetics Inc | COM | 62855J104 | — | 5,735,000 shares | $32,746,850 |
| Rapport Therapeutics Inc | COM | 75383L102 | — | 730,000 shares | $30,419,100 |
| Crescent Biopharma Inc | COM | G2545C104 | — | 1,630,000 shares | $29,340,000 |
| GE HealthCare Technologies Inc | COMMON STOCK | 36266G107 | — | 450,000 shares | $28,804,500 |
| Insmed Inc | COM PAR $.01 | 457669307 | — | 250,000 shares | $26,655,000 |
| Viking Therapeutics Inc | COM | 92686J106 | — | 680,000 shares | $26,526,800 |
| Beta Bionics Inc | COM | 08659B102 | — | 1,600,000 shares | $25,072,000 |
| Regeneron Pharmaceuticals Inc | COM | 75886F107 | — | 40,000 shares | $24,941,600 |
| Solid Biosciences Inc | COM NEW | 83422E204 | — | 2,160,000 shares | $21,578,400 |
| Alto Neuroscience Inc | COM SHS | 02157Q109 | — | 785,000 shares | $20,716,150 |
| First Tracks Biotherapeutics I | ORD SHS | 337185102 | — | 1,013,000 shares | $20,381,560 |
| Lexeo Therapeutics Inc | COM | 52886X107 | — | 4,320,000 shares | $20,109,600 |
| Savara Inc | COM | 805111101 | — | 2,720,000 shares | $16,755,200 |
| Damora Therapeutics Inc | COM NEW | 36322Q206 | — | 575,000 shares | $14,955,750 |
| SpyGlass Pharma Inc | COM SHS | 85220G109 | — | 670,000 shares | $14,914,200 |
| Tectonic Therapeutic Inc | COM | 878972108 | — | 425,000 shares | $14,609,375 |
| Avalo Therapeutics Inc | COM NEW | 05338F306 | — | 775,000 shares | $14,322,000 |
| Evommune Inc | COM SHS | 30054Y107 | — | 1,000,000 shares | $13,290,000 |
| Kailera Therapeutics Inc | COMMON STOCK | 482931102 | — | 575,000 shares | $12,667,250 |
| Anteris Technologies Global Co | COM | 03675P102 | — | 1,010,000 shares | $9,948,500 |
| Zenas Biopharma Inc | COM | 98937L105 | — | 365,000 shares | $9,263,700 |
| Voyager Therapeutics Inc | COM | 92915B106 | — | 2,625,000 shares | $9,187,500 |
| OnKure Therapeutics Inc | COM CL A | 68277Q105 | — | 1,825,699 shares | $8,325,187 |
| Surrozen Inc | COM NEW | 86889P208 | — | 304,669 shares | $7,906,161 |
| Monopar Therapeutics Inc | COM NEW | 61023L207 | — | 75,727 shares | $7,011,563 |
| Zura Bio Ltd | CLASS A ORD SHS | G9TY5A101 | — | 1,173,956 shares | $6,926,340 |
| Olema Pharmaceuticals Inc | COM | 68062P106 | — | 418,551 shares | $5,236,073 |
| Palisade Bio Inc | COM | 696389402 | — | 2,500,000 shares | $5,225,000 |
| iBio Inc | COM NEW | 451033708 | — | 2,600,000 shares | $4,550,000 |
| Sagimet Biosciences Inc | COM SER A | 786700104 | — | 535,452 shares | $4,139,044 |
| enGene Therapeutics Inc | COM | 29286X101 | — | 1,667,430 shares | $2,884,654 |
| Rezolute Inc | COM NEW | 76200L309 | — | 382,999 shares | $1,991,595 |
| Nyxoah SA | SHS | B6S7WD106 | — | 843,461 shares | $1,425,449 |
| Tenax Therapeutics Inc | COM NEW | 88032L605 | — | 53,439 shares | $777,537 |
| Aprea Therapeutics Inc | COM NEW | 03836J201 | — | 350,000 shares | $280,805 |